Last reviewed · How we verify
Refractory chronic lymphocytic leukemia
Approved treatments
- Campath · National Heart, Lung, and Blood Institute (NHLBI)
- Campath · Sanofi
Campath works by binding to a specific protein on the surface of immune cells, marking them for destruction.
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Refractory chronic lymphocytic leukemia patent landscape — cliff calendar, originator estates, attackable patents
- Refractory chronic lymphocytic leukemia treatment landscape brief
- Refractory chronic lymphocytic leukemia treatment updates RSS
Frequently asked questions about Refractory chronic lymphocytic leukemia
What drugs treat Refractory chronic lymphocytic leukemia?
Tracked treatments include Campath.
What is the treatment for Refractory chronic lymphocytic leukemia?
Standard treatment for Refractory chronic lymphocytic leukemia includes Campath. See the treatment landscape page for first-line, second-line and salvage options.
Related
- Treatment landscape: Refractory chronic lymphocytic leukemia patent cliff · Refractory chronic lymphocytic leukemia CI report
- Treatment: Campath · National Heart, Lung, and Blood Institute (NHLBI)
- Treatment: Campath · Sanofi
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing